Leap Therapeutics (NASDAQ:LPTX) Receives New Coverage from Analysts at Rodman & Renshaw

Rodman & Renshaw assumed coverage on shares of Leap Therapeutics (NASDAQ:LPTX) in a report published on Friday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $8.00 target price on the stock.

A number of other analysts also recently weighed in on the company. HC Wainwright dropped their target price on Leap Therapeutics from $7.00 to $5.50 and set a buy rating for the company in a research report on Tuesday, May 14th. Robert W. Baird dropped their target price on Leap Therapeutics from $11.00 to $9.00 and set an outperform rating for the company in a research report on Tuesday, March 19th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of Buy and a consensus target price of $10.40.

Leap Therapeutics Trading Down 4.6 %

Shares of LPTX opened at $1.87 on Friday. The company has a market cap of $47.87 million, a PE ratio of -0.78 and a beta of 0.32. The stock has a 50-day moving average price of $2.50 and a 200-day moving average price of $2.86. Leap Therapeutics has a 12-month low of $1.24 and a 12-month high of $5.00.

Leap Therapeutics (NASDAQ:LPTX) last issued its quarterly earnings results on Monday, May 13th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.06. As a group, analysts predict that Leap Therapeutics will post -1.66 earnings per share for the current year.

Hedge Funds Weigh In On Leap Therapeutics

A number of large investors have recently bought and sold shares of LPTX. Vanguard Group Inc. increased its stake in Leap Therapeutics by 111.7% in the 1st quarter. Vanguard Group Inc. now owns 867,708 shares of the company’s stock worth $2,308,000 after purchasing an additional 457,904 shares during the period. Acuta Capital Partners LLC purchased a new position in shares of Leap Therapeutics during the third quarter valued at approximately $489,000. Acadian Asset Management LLC increased its stake in shares of Leap Therapeutics by 349.3% during the first quarter. Acadian Asset Management LLC now owns 282,413 shares of the company’s stock valued at $750,000 after buying an additional 219,563 shares during the period. 683 Capital Management LLC increased its stake in shares of Leap Therapeutics by 60.7% during the third quarter. 683 Capital Management LLC now owns 490,000 shares of the company’s stock valued at $676,000 after buying an additional 185,001 shares during the period. Finally, Key Client Fiduciary Advisors LLC increased its stake in shares of Leap Therapeutics by 43.3% during the third quarter. Key Client Fiduciary Advisors LLC now owns 227,273 shares of the company’s stock valued at $314,000 after buying an additional 68,676 shares during the period. 30.46% of the stock is owned by hedge funds and other institutional investors.

About Leap Therapeutics

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.